Evidence-Based Diabetes Management > March 2016

Evidence-Based Diabetes Management - March 2016

March 15, 2016 – Andrew Smith
Did MannKind misjudge consumer demand, or are barriers from payers to blame for Afrezza's woes? A feature outlining the misfortunes and future plans for the only inhaled insulin on the market.
March 16, 2016 – Joanna Mitri, MD, MS; Robert A. Gabbay, MD, PhD, FACP
An introduction to the Joslin Clinical Analytic Tool, a new diabetes measure developed to adjust for the variety in patient mix and better inform clinicians which interventions will work best.
March 16, 2016 – Helen Burstin, MD, MPH; Karen Johnson, MS
Authors from the National Quality Forum discuss development of the next generation of diabetes measures, including those that reflect "the voice of the patient."
March 16, 2016 – Ian Hargaves, PhD; Rene Rodriguez-Gutierrez, MD; Victor M. Montori, MD, MSC
Authors from the Mayo Clinic discuss situational goals in diabetes care, because quality targets enforced too strictly may harm patients who are working hard to manage their disease.
March 18, 2016 – Kenneth J. Snow, MD, MBA
A case management program implemented by Coventry Healthcare in one of the nation's poorest areas produced positive, measurable results among patients with diabetes.
March 18, 2016 – Shana B. Traina, PhD; April Slee, MS
Questionnaires are noninvasive, inexpensive measures that can identify key elements of the patient perspec­tive that are important for the achievement of better outcomes in diabetes care.
March 18, 2016 – Lee Barrett
If healthcare reimbursement is to rely on patient data, providers must take care to protect information from breaches.
March 18, 2016 – Robert A. Gabbay, MD, PhD, FACP
Dr Gabbay is editor in chief of Evidence-Based Diabetes Management.
March 18, 2016 – Joseph Manganelli, PharmD, MPA
Medication therapy management is a key component of ensuring good outcomes in diabetes care. The clinical pharmacist can play a key role in ensuring good transitions of care, avoiding problems of polypharmacy, addressing financial issues, and providing patient education.
March 18, 2016 – Ralph McDade, PhD
The availability of a novel predictive biomarker in diabetes care could have benefits for patients, payers, and pharma.
March 18, 2016 – Mary Caffrey
In Soda Politics, Marion Nestle, PhD, traces the history of the giant soda companies in the United States, and how they have copied the tactics of Big Tobacco to get children "drinking sugar," with resulting rates of diabetes and obesity. Other groups are joining Nestle in criticizing the export of heavy soda marketing to the developing world.
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.